Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Express Scripts
Teva
Colorcon
McKinsey
US Army
Moodys
Healthtrust
AstraZeneca
Fish and Richardson

Generated: December 11, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR CARFILZOMIB

« Back to Dashboard

Clinical Trials for Carfilzomib

Trial ID Title Status Sponsor Phase Summary
NCT00150462 Safety Study of the Proteasome Inhibitor PR-171 (Carfilzomib for Injection) in Patients With Hematological Malignancies Completed Onyx Pharmaceuticals Phase 1 The purpose of this study is to test the safety and tolerability of carfilzomib at different dose levels on hematological cancers such as multiple myeloma, non-Hodgkin's lymphoma, Hodgkin's disease, or Waldenstrom's macroglobulinemia. Carfilzomib is a proteasome inhibitor, an enzyme responsible for degrading a wide variety of cellular proteins.
NCT00461045 Phase 1/2 Clinical Trial of NPI-0052 in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma Unknown status Triphase Research and Development I Corporation Phase 1/Phase 2 This is a Phase 1/2, open-label, multicenter study examining the safety, pharmacokinetics and pharmacodynamics, and best overall response to escalating doses of the proteasome inhibitor NPI-0052 in patients with relapsed or relapsed/refractory multiple myeloma. NPI-0052 is a novel, second generation proteasome inhibitor that prevents the breakdown of proteins involved in signal transduction which blocks growth and survival in cancer cells. The study is divided into 2 parts: Part 1 is Phase 1 and explores 2 different schedules of NPI-0052 to determine the maximum tolerated dose and/or recommended phase 2 dose (Schedules A [once weekly dosing] and B [twice-weekly dosing]). Part 2 is Phase 2 and is a 2-stage efficacy design in a selected subgroup of patients treated with Schedule B at the recommended phase 2 dose, as determined in Part 1. Amendment 13 to the protocol is currently recruiting to evaluate the safety and any preliminary evidence of efficacy of NPI-0052 in multiple myeloma patients who have previously received carfilzomib (PR-171, Kyprolis™) and subsequently had disease progression. Patients in Part 2 will be followed for survival for up to 5 years from date of first dose.
NCT00511238 Phase 2 Study of Carfilzomib in Relapsed and Refractory Multiple Myeloma Completed Onyx Therapeutics, Inc. Phase 2 To evaluate the overall response rate and safety and tolerability of carfilzomib in subjects with relapsed and refractory multiple myeloma. Patients must have received prior treatment with bortezomib and either thalidomide or lenalidomide and be refractory to their last treatment.
NCT00530816 Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma Completed Onyx Therapeutics, Inc. Phase 2 To evaluate the best overall response rate, safety and tolerability of carfilzomib in patients with relapsed or refractory multiple myeloma.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Carfilzomib

Condition Name

Condition Name for Carfilzomib
Intervention Trials
Multiple Myeloma 79
Lymphoma 7
Myeloma 7
Refractory Multiple Myeloma 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Carfilzomib
Intervention Trials
Multiple Myeloma 116
Neoplasms, Plasma Cell 115
Lymphoma 19
Lymphoma, Non-Hodgkin 8
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Carfilzomib

Trials by Country

Trials by Country for Carfilzomib
Location Trials
United States 563
Canada 39
Japan 36
United Kingdom 28
Germany 21
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Carfilzomib
Location Trials
New York 41
California 39
Texas 37
Illinois 30
New Jersey 28
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Carfilzomib

Clinical Trial Phase

Clinical Trial Phase for Carfilzomib
Clinical Trial Phase Trials
Phase 4 1
Phase 3 12
Phase 2 61
[disabled in preview] 38
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Carfilzomib
Clinical Trial Phase Trials
Recruiting 63
Active, not recruiting 36
Not yet recruiting 24
[disabled in preview] 19
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Carfilzomib

Sponsor Name

Sponsor Name for Carfilzomib
Sponsor Trials
Onyx Therapeutics, Inc. 35
Onyx Pharmaceuticals 27
National Cancer Institute (NCI) 20
[disabled in preview] 12
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Carfilzomib
Sponsor Trials
Other 139
Industry 130
NIH 20
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Department of Justice
Accenture
Healthtrust
UBS
Dow
Cerilliant
Julphar
US Army
QuintilesIMS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.